Selected Portfolio Companies
Akeso, Inc. (9926.HK) is a biopharmaceutical
company dedicated to
the research,
development,
manufacturing and commercialization of new innovative antibody
drugs that are affordable
to patients worldwide.
- Year Invested 2019
- Therapeutic Area Oncology,Immunology, Inflammation, Metabolic Disease, etc.
- Area of Technology Biologics
- Status Public
- Location Guangdong, China
- https://www.akesobio.com/en/
AMBRX (NYSE: AMAM) is a pioneering biotechnology company focused on creating next-generation antibody drug conjugates (ADCs) for a variety of cancers indications.
- Year Invested 2017
- Therapeutic Area Oncology
- Area of Technology ADC
- Status Acquired
- Location La Jolla, CA
- https://ambrx.com
Argo Biopharma is a clinical-stage biotech company that is commited to developing a new generation of siRNA drugs to provide better treatments for global patients.
- Year Invested 2021
- Therapeutic Area Multiple Indications
- Area of Technology RNA
- Status Private
- Location Shanghai, China
- https://www.argobiopharma.com
Arnatar uses various cutting-edge RNA targeting antisense technologies to develop novel therapies that modulate the origin of the diseases, by reducing or increasing the expression of specific genes that cause or contribute to disease.
- Year Invested 2021
- Therapeutic Area Multiple Indications
- Area of Technology RNA
- Status Private
- Location Jiangsu, China
- https://www.arnatar.com
CirCode team has developed a proprietary technology platform that can robustly produce circRNAs in a large scale with high translation efficiency.This technology has been applied in developing explore more effective therapeutic drugs.
- Year Invested 2021
- Therapeutic Area Multiple Indications
- Area of Technology RNA
- Status Private
- Location Shanghai, China
- https://www.circodebio.cn/en/
D2M Biotherapeutics is a research-driven company focused on discovering and developing innovative therapeutics to address unmet medical needs in oncology and autoimmune diseases.
- Year Invested 2020
- Therapeutic Area Oncology, Immunology
- Area of Technology Biologics
- Status Private
- Location Shanghai, China
Evopoint Biosciences is an innovative biopharmaceutical company with exceptional R&D and commercialization capabilities. Since its inception, Evopoint has been committed to improving human health by providing cutting-edge pharmaceutical solutions to address significant unmet medical needs globally.
- Year Invested 2018
- Therapeutic Area Oncology, Infectious Diseases and Metabolic Diseases
- Area of Technology Targeted Therapy, Next-generation ADCs, and Targeted Protein Degradation (TPD)
- Status Private
- Location Jiangsu, China
- https://www.evopointbio.com/en
Guobang Pharma (605507.SH), a top 100 pharmaceutical enterprise in China, is a global and diversified pharmaceutical manufacturer, equipped with distinct supply chains and a complete industrial platform.
- Year Invested 2019
- Area of Technology Active Pharmaceutical Ingredients, Key Pharmaceutical Intermediates and Preparations
- Status Public
- Location Zhejiang, China
- https://www.gbgcn.com/about_en.html
Lumiere Therapeutics is a global biotech leader specializing in epigenetic editing technologies and delivery systems. With proprietary intellectual property, Lumiere is developing therapeutics as one-time cures for metabolic diseases and infectious diseases, including hepatitis B, hyperlipidemia, and glaucoma.
- Year Invested 2021
- Therapeutic Area Metabolic Diseases and Infectious Diseases
- Area of Technology Gene Therapy
- Status Private
- Location Jiangsu, China
LyncBio Therapeutics is a pioneering biotech company in China developing next-generation antibody-drug conjugates (ADCs) for autoimmune diseases. Leveraging world-leading technologies and the expertise of its founding team, LyncBio is uniquely positioned to advance innovative ADC therapies in the immunology space.
- Year Invested 2023
- Therapeutic Area Immunology
- Area of Technology ADC
- Status Private
- Location Shanghai, China
MedLink Therapeutics is focused on antibody-drug conjugates (ADCs), utilizing its proprietary TME-specifically cleavable camptothecin (TMALIN®) toxin conjugate platform. This platform has enabled the development of ten ADC products approved for clinical studies in both China and the United States.
- Year Invested 2021
- Therapeutic Area Oncology
- Area of Technology ADC
- Status Private
- Location Jiangsu, China
- https://www.medilinkthera.com
Nikegen is an innovative biotech company dedicated to developing next-generation AAV-delivered gene therapies. By overcoming the limitations of current gene therapy approaches, Nikegen is pioneering safer and more effective gene therapies for a variety of diseases.
- Year Invested 2021
- Therapeutic Area Multiple Indications
- Area of Technology Gene Therapy
- Status Private
- Location Zhejiang, China
Qi Biodesign is committed to developing novel, independent and precise gene editing technologies, aiming to create excellent biological traits and products. The company has established the SEEDIT™ biotechnology and trait engineering platform featuring high efficiency, high throughput and sustainable learning capabilities.
- Year Invested 2021
- Therapeutic Area Genetics, Botany
- Area of Technology Gene Editing
- Status Private
- Location Beijing, China
- http://www.qi-biodesign.com/#/home
RemeGen (688331.SH, 09995.HK) is committed to the discovery development and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.
- Year Invested 2020
- Therapeutic Area Immunology, Oncology and Ophthalmology
- Area of Technology Biological Drug
- Status Public
- Location Shandong, China
- https://www.remegen.com
Sinomab (03618.HK) is dedicated to the research, development, manufacturing, and commercialization of therapeutics for immunological diseases. With a pipeline of potential first-in-class drug candidates, Sinomab is addressing major unmet clinical needs in rheumatoid arthritis, lupus, atopic dermatitis, and other autoimmune conditions.
- Year Invested 2017
- Therapeutic Area Immunology
- Area of Technology Biologics
- Status Public
- Location Hong Kong, China
- http://www.sinomab.com
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs.
- Year Invested 2019
- Therapeutic Area Oncology, Immunology
- Area of Technology Biologics
- Status Private
- Location Jiangsu, China
- https://www.tavotek.com
Junshi Biosciences (01877.HK, 688180.SH) is an innovation-driven biopharmaceutical company committed to developing first-in-class and best-in-class drugs. With a strong focus on onco-immunotherapy and treatments for autoimmune, metabolic, neurological, and infectious diseases.
- Year Invested 2016
- Therapeutic Area Oncology, Immunology
- Area of Technology Biologics
- Status Public
- Location Shanghai, China
- https://www.junshipharma.com/en/
VivaTides Therapeutics is pioneering extrahepatic delivery of oligonucleotide therapeutics. With novel chemistry innovations, VivaTides is developing oligonucleotide therapies with enhanced tissue specificity and safety profiles, targeting tissues beyond the liver, including the CNS and adipose tissue.
- Year Invested 2024
- Therapeutic Area Multiple Indications
- Area of Technology RNA
- Status Private
- Location Jiangsu, China
BCIFlix is a medical technology company specializing in high-throughput invasive flexible brain-computer interface (BCI) technology. Focused on enabling precise diagnosis and treatment of nervous system diseases, BCIFlix is pushing the boundaries of neurotechnology.
- Year Invested 2022
- Therapeutic Area CNS
- Area of Technology Brain-computer Interface
- Status Private
- Location Beijing, China
BioLink is a high-tech group enterprise that provides process solutions for the life science industry. We focus on the R&D and manufacturing of equipment and consumables in the production of recombinant protein drugs, vaccines, antibody drugs, cell therapy, gene therapy, and other biological products.
- Year Invested 2022
- Area of Technology Bioprocessing Products
- Status Private
- Location Shanghai, China
- https://www.biolink.com
Eden Rad is focused on the research, development, and production of advanced electro-vacuum products. The products are widely applied in the fields of medical imaging and industrial inspection, including medical CT X-ray tubes and high-end industrial micro-focus X-ray tubes.
- Year Invested 2023
- Therapeutic Area Diagnosis
- Area of Technology CT X-ray Tubes
- Status Private
- Location Jiangsu, China
EverPace (688351.SH) is dedicated to the research, development, production, and sales of innovative medical devices for electrophysiological interventions and ablation therapy. Committed to providing integrated solutions for precise interventional navigation, EverPace is a leader in electrophysiology.
- Year Invested 2016
- Therapeutic Area Electrophysiology
- Area of Technology Cardiovascular, Cerebrovascular Devices
- Status Public
- Location Shanghai, China
- https://microport.com
Infivision focuses on innovative and development of EIT imaging technology. Through its products and services, it provides the world with high-end medical imaging products and solutions that are continuous, real-time, bedside, non-radiative, and non-invasive.
- Year Invested 2023
- Therapeutic Area Clinical Detection
- Area of Technology Medical Electrical Impedance Tomography (EIT)
- Status Private
- Location Beijing, China
- https://www.infivision.com
MicroPort (00853.HK) is a global leader in medical devices, focusing on innovative transcatheter and surgical solutions for structural heart disease. Its second-generation transcatheter aortic valve implantation (TAVI) product, VitaFlow Liberty®, is the world's only commercially available electrically retrievable TAVI product.
- Year Invested 2016
- Therapeutic Area Heart Valve
- Area of Technology Cardiovascular and Cerebrovascular Devices
- Status Public
- Location Shanghai, China
- https://microport.com
Sierra Medical is an innovative medical device company committed to providing precise and intelligent minimally invasive surgical solutions in ophthalmology. Integrating R&D, production, and sales, Sierra Medical is dedicated to advancing ophthalmic treatment and improving vision care.
- Year Invested 2023
- Therapeutic Area Ophthalmology
- Area of Technology Ophthalmic Treatment Devices
- Status Private
- Location Jiangsu, China
United InnoMed is dedicated to the research and development of novel medical devices for the treatment and management of heart failure. With a mission to improve the quality of life and save lives of heart failure patients, United InnoMed is developing innovative solutions in cardiovascular care.
- Year Invested 2022
- Therapeutic Area Heart Failure
- Area of Technology Heart Failure Medical Device
- Status Private
- Location Shanghai, China
Bellen Chemistry is providing chemistry CRO/CDMO services as an integrated Contract Chemistry Service Organization (CCSO). With years of accumulated technical advantages and experiences in chemical synthesis of small molecule compounds, Bellen has built a one-stop shop chemistry service platform, supporting global pharmaceutical companies, biotech innovators and new drug development institutions for their research programs from discovery to commercial stage through comprehensive chemistry solutions.
- Year Invested 2018
- Therapeutic Area CDMO
- Status Private
- Location Beijing, China
- https://www.bellenchem.com/en
PHARMCUBE strives to reconstruct pharmaceutical data, bridge the information gap, and thoroughly empower innovation.
- Year Invested 2016
- Therapeutic Area Pharmaceutical Data
- Status Private
- Location Shanghai, China
- https://www.pharmcube.com
Shengsheng is a pharmaceutical cold chain service provider, offering integrated solutions for life sciences, biotechnology, drug R&D, and commercial pharmaceuticals. Covering the entire cold chain, Shengsheng ensures the integrity and safety of temperature-sensitive products.
- Year Invested 2018
- Therapeutic Area Pharmaceutical Cold Chain
- Status Private
- Location Shanghai, China
- https://shengshengscm.com
TriApex is an innovative CRO dedicated to providing integrated solutions and enabling the specialized disease-oriented R&D for global pharmaceutical enterprises and research institutions.Relying on the top technical service team in the industry to build and improve group management, TriApex focuses on the pathogenesis and models of diseases, nonclinical research, and clinical and translational research by means of highly scientific and professional operation strategies.
- Year Invested 2021
- Therapeutic Area CRO
- Status Private
- Location Jiangsu, China
- https://www.tri-apex.com
